US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cynata Therapeutics Ltd.

0.1500

0.0000

Volume:- -

Turnover:- -

Market Cap:35.62M

PE:-4.98

High:0.1500

Open:0.1500

Low:0.1500

Close:0.1500

52wk High:0.1900

52wk Low:0.0800

Shares:237.45M

Float Shares:182.80M

Volume Ratio:0.24

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0301

EPS(LYR):-0.0362

ROE:-142.29%

ROA:-77.08%

PB:8.96

PE(LYR):-4.14

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Cynata Therapeutics Ltd.

Exchange:

PINK LIMITED

Establishment Date:

2003

Employees:

2

Office Location:

100 Cubitt Street,Level 3,Cremorne,Victoria,Australia

Website:

- -

Zip Code:

3121

Phone:

Fax:

61 3 7067 6940

Introduction:

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CYYNF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYYNF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYYNF\",,,,,undefined,":{"symbol":"CYYNF","market":"US","secType":"STK","nameCN":"Cynata Therapeutics Ltd.","latestPrice":0.15,"timestamp":1764968400000,"preClose":0.15,"halted":0,"volume":0,"delay":15,"floatShares":182795745,"shares":237454369,"eps":-0.030095,"marketStatus":"Market Closed","change":0,"latestTime":"12-05 16:00:00 EST Delay","open":0.15,"high":0.15,"low":0.15,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.030095,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":0.15,"volumeRatio":0.2448519818779123},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYYNF\",,,,,undefined,":{"symbol":"CYYNF","floatShares":182795745,"roa":"-77.08%","roe":"-142.29%","lyrEps":-0.036194,"volumeRatio":0.2448519818779123,"shares":237454369,"dividePrice":0,"high":0.15,"amplitude":0,"preClose":0.15,"low":0.15,"week52Low":0.08,"pbRate":"8.96","psRate":"28.45","week52High":0.19,"institutionHeld":0,"latestPrice":0.15,"eps":-0.030095,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.030095,"open":0.15,"prevYearClose":0.19,"prevWeekClose":0.15,"prevMonthClose":0.15,"prevQuarterClose":0.118,"fiveDayClose":0.15,"twentyDayClose":0.118,"sixtyDayClose":0.118},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYYNF\",params:#limit:5,,,undefined,":[{"date":"2024-05-08","symbol":"CYYNF","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715198400000,"name":null,"time":"Post Market","dateTimestamp":1715140800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYYNF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CYYNF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1764133200000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":38323454,"yearFounded":2003,"employeeNum":2,"address":"100 Cubitt Street,Level 3,Cremorne,Victoria,Australia","zipCode":"3121","officePhone":"61 3 7067 6940","officeFax":"61 3 7067 6940"},"stockCompanyDetail":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0.4167},{"period":"6month","weight":0.2593},{"period":"1year","weight":0.2526},{"period":"ytd","weight":0.5867}],"description":"Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.","exchange":"PINK LIMITED","name":"Cynata Therapeutics Ltd.","nameEN":"Cynata Therapeutics Ltd."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CYYNF\",market:\"US\",,,undefined,":null}}